The purpose of Core 2 Biostatistics is to provide statistical support to the four Projects as well as to the initiatives involving clinical studies through Core 3 and statistical assessment of biospecimens through Core 1, all toward the goal of development of curative options for patients with AML, MDS, and CMML. This Core assures that the design, conduct, and analyses of all experiments?clinical, correlative, animal, or basic science- -use robust statistical techniques that are appropriately implemented. This central resource thereby helps to elucidate the mechanisms as well as the vulnerabilities of myeloid malignancies.

Public Health Relevance

- Core 2 Biostatistics The goal of Core 2 Biostatistics is to assure that all experiments conducted through this P01 in in myeloid malignancies have access to state-of-the-art statistical support for their design and analysis. This extends to the basic science and murine experiments described in the four Projects, as well as to the clinical and correlative studies undertaken in conjunction with the Clinical Core (Core 3) and the Biospecimen Core (Core 1). This assures that the work performed on this P01 will be robust and reproducible, and thereby contribute to an improved understanding of these diseases.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Nauffal, Mary; Redd, Robert; Ni, Jian et al. (2018) Single 6-mg dose of rasburicase: The experience in a large academic medical center. J Oncol Pharm Pract :1078155218791333
Stein, Eytan M; Garcia-Manero, Guillermo; Rizzieri, David A et al. (2018) The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood 131:2661-2669
Hemming, Matthew L; Lawlor, Matthew A; Zeid, Rhamy et al. (2018) Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proc Natl Acad Sci U S A 115:E5746-E5755
Kardosova, Miroslava; Zjablovskaja, Polina; Danek, Petr et al. (2018) C/EBP? is dispensable for steady-state and emergency granulopoiesis. Haematologica 103:e331-e335
Numata, Akihiko; Kwok, Hui Si; Kawasaki, Akira et al. (2018) The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia. Nat Commun 9:1622
Brown, Fiona C; Still, Eric; Koche, Richard P et al. (2018) MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov 8:478-497
Manley, Paul W; Weisberg, Ellen; Sattler, Martin et al. (2018) Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series ""Biochemistry to Bedside"". Biochemistry 57:477-478
Ebert, Benjamin L; Libby, Peter (2018) Clonal Hematopoiesis Confers Predisposition to Both Cardiovascular Disease and Cancer: A Newly Recognized Link Between Two Major Killers. Ann Intern Med 169:116-117
DiNardo, Courtney D; Pratz, Keith W; Letai, Anthony et al. (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19:216-228
Brien, Gerard L; Remillard, David; Shi, Junwei et al. (2018) Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife 7:

Showing the most recent 10 out of 376 publications